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Abstract
Motivation: Complex diseases induce perturbations to interaction and regulation networks in living systems, resulting
in dynamic equilibrium states that differ for different diseases and also normal states. Thus identifying gene expression
patterns corresponding to different equilibrium states is of great benefit to the diagnosis and treatment of complex
diseases. However, it remains a major challenge to deal with the high dimensionality and small size of available
complex disease gene expression datasets currently used for discovering gene expression patterns.
Results: Here we present a phase-only correlation (POC) based classification method for recognizing the type of
complex diseases. First, a virtual sample template is constructed for each subclass by averaging all samples of each
subclass in a training dataset. Then the label of a test sample is determined by measuring the similarity between
the test sample and each template. This novel method can detect the similarity of overall patterns emerged from
the differentially expressed genes or proteins while ignoring small mismatches.
Conclusions: The experimental results obtained on seven publicly available complex disease datasets including
microarray and protein array data demonstrate that the proposed POC-based disease classification method is
effective and robust for diagnosing complex diseases with regard to the number of initially selected features, and
its recognition accuracy is better than or comparable to other state-of-the-art machine learning methods. In
addition, the proposed method does not require parameter tuning and data scaling, which can effectively reduce
the occurrence of over-fitting and bias.
Introduction
Classification and diagnostic prediction of complex dis-
eases such as cancers and neuron-degeneration diseases
using genomic or proteomic data can improve the quality
of pathological diagnosis and help develop personalized
treatment of these diseases [1]. Although great efforts
have been exerted in this field, making early and precise
diagnosis of complex diseases, followed through with
effectively treating remains a great challenge. For exam-
ple, the histological methods cannot precisely distinguish
between the subtypes of some cancers [2] that the devel-
opment of effective therapies depends on. The molecular
mechanisms of many neuron-degeneration diseases such
as Alzerheimer’s (AD) and Parkinson’s (PD) diseases are
not fully understood and diagnosis of these diseases rely
on medical history evaluation and the combination of
physical and neurological assessments [3,4], often after
irreversible brain damage or mental decline already
occurs.
The rationale of classification and diagnostic prediction
of complex diseases using genomic or proteomic data is
based on the assumption that complex diseases induce
perturbations to interaction and regulation networks of
living systems, resulting in dynamic equilibrium states
that differ for different diseases and also normal states.
Thus identifying gene expression patterns corresponding
to different equilibrium states is a key task to the success
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of these types of approaches. Many pattern recognition
methods based on machine learning, such as k-nearest
neighbor (KNN), support vector machines (SVM) [5-7],
probabilistic neuron networks (PNN) [8-10], naive Bayes
model (NBM) [11] and random forest (RF) [4,12], etc.,
have been extensively explored for the classification and
diagnostic prediction of complex diseases [13]. Usually,
these supervised learning methods are called model-
based ones because a classification model needs to be
constructed using a training set before it can be used to
predict the label of a test sample. However, for the
model-based methods, feature extraction and feature
selection techniques play a vital role in improving
the performance of complex disease classification due to
the high-dimensionality and small sample size of GEP
dataset.
An example of feature extraction methods is that inde-
pendent component analysis (ICA) was used to extract
independent components from GEP to reduce the dimen-
sionality of sample [7,14,15]. Other feature extraction
methods such as principal component analysis (PCA) [6],
linear discriminant analysis (LDA) [16] and locally linear
discriminant embedding (LLDE) [17] are also extensively
applied to the dimensionality reduction of GEP. Although
such methods can achieve satisfactory classification perfor-
mance, there is weak biomedical interpreter and signifi-
cance. An example of gene selection methods is that the
Classification to Nearest Centroids (ClaNC) method for
class-specific gene selection was proposed to determine a
gene subset of given size that maximizes the classification
accuracy [18]. Although such methods have biomedical
meaning, there are a great number of gene subsets with
the same predictive performance, which could lead to the
selection arbitrariness of candidate gene subsets. In fact,
each method has its drawbacks, and many factors such as
normalization, small sample size, noisy data, improper eva-
luation methods, and too many model parameters can lead
to the over-fitting of the constructed model, the bias of
results and false discovery [19-22]. Even so, “microarrays
remain a useful technology to address a wide array of bio-
logical problems and the optimal analysis of these data to
extract meaningful results still pose many bioinformatics
challenges.” [23]. Therefore, with the increasing accumula-
tion of GEP and protein microarray data, it is still neces-
sary to design more effective and more biomedical
methods to recognize complex disease type, which is also
the requirement of clinical application.
For potential clinical applications, a candidate classifica-
tion model should be evaluated for three aspects: accuracy,
interpretability and practicality [18]. And a novel method
should be measured up from three aspects. 1) A good
model should be simple and have no or few parameters to
be tuned. If parameters are necessary, the model should be
robust with regard to the variation of these parameters.
2) The obtained model should achieve the best or near-
optimal performance of disease classification as compared
to the relevant state-of-the-art methods because there is
no classification method that always outperforms all
others in all circumstances [23,24]. 3) The obtained model
should be obviously interpretable from biomedical per-
spective, which requires that the intrinsic signatures of
sample set should be used as designing the classification
model.
Previous studies suggest that each complex disease type
or subtype corresponds to a dynamic equilibrium state of
disease-induced genomic interaction and regulation net-
work, and different samples at the same state are similar
in gene expression profiles [25]. Thus analyzing the simi-
larity level of gene expression profiles can be in principle
used to distinguish different disease types or subtypes. A
gene expression profile, which comprises the expression
levels of numerous genes, can be likened to a digital image
that consists of the luminance of pixels. In fact, both
microarray and protein array data are originated from digi-
tal images. We therefore suggest that it is reasonable to
apply some image processing methods to analyze genomic
and proteomic data. Based on this idea, recently we suc-
cessfully proposed two correlation filters based on tumor
classification methods, namely, minimum average correla-
tion energy (MACE) and optimal tradeoff synthetic discri-
minant function (OTSDF), to identify the overall pattern
of differentially expressed genes (DEGs), corresponding to
the tumor subtypes [26]. Although the two methods per-
form well in classifying tumor subtypes, they have some
drawbacks: 1) The two methods are sensitive to the data
scaling methods used to standardize the data; 2) although
the template synthesized for each subtype in frequency
domain space can be used to characterize the correspond-
ing subtype, the biomedical significance of the synthesized
template itself is not obvious enough. Thus it is highly
desirable to explore other correlation methods which can
recognize disease types well but without the weaknesses of
the MACE and OTSDF-based disease classification
methods.
Our further experiments indicate that phase-only corre-
lation (POC) [27] may be such a method. Like the MACE
and OTSDF filters, POC also utilizes a fast frequency
domain approach to estimate the similarity degree
between two samples. In recent years POC has also been
extensively applied to image recognition [28,29] and iden-
tification of seismic events [30]. In this study, we present a
novel POC-based method to complex disease classification
based on virtual sample templates using genomic or pro-
teomic data. First, we construct one template for each sub-
class on a training set. Sample matching can then be
performed by cross-correlating a test sample with each
template in training set using POC and analyzing the
resulting correlation output. By comparing the peaks of
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correlation output, the test sample can be easily assigned
to the class for which the template with the highest simi-
larity to the test sample represents.
Methods
Complex disease datasets
Seven public available complex disease datasets are used to
evaluate the proposed method in our experiments. They
include the Leukemia1 [31], GSE29676 (http://www.ncbi.
nlm.nih.gov) [3,4], Leukemia2 [32], small round blue cell
tumor (SRBCT) [33], GSE5281 (http://www.ncbi.nlm.nih.
gov) [34], colon tumor (Colon) [35], and GCM [36] data-
sets. The Leukemia1 dataset contains 72 samples from
three subtypes or subclasses, i.e., MLL, AML and ALL.
The GSE29676 dataset includes 50 Alzheimer’s disease
and 29 Parkinson’s disease samples as well as 40 non-
demented control samples. The Leukemia2 dataset con-
tains 72 samples and 7,129 genes from three subclasses,
i.e., AML, ALL-T and ALL-B. The GSE5281 dataset
includes 71 normal samples and 87 Alzheimer samples.
The SRBCT dataset consists of four subclasses, i.e.,
Ewing’s sarcoma (EWS), Burkitt’s (BL), Neuroblastoma
(NB), and rhabdomyosarcoma (RMS). The GCM dataset
consists of fourteen different tumor types. These datasets
are summarized in Table 1.
Both protein and DNA microarray data can be repre-
sented with matrices. Thus we use DNA microarray data
as an example to describe the design of our method.
Let G = {g1, g2, · · · , gN} denote a set of N genes, and
S = {f1(s), f2(s), · · · , fM(s)} denote a set containing M
samples, where fm (s) =
(
xm,1, · · · xm,n, · · · xm,N
)′, 1 ≤ m ≤ M, 1 ≤ n ≤ N
denotes the gene expression column vector of the corre-
sponding sample sm on all N features. Each sample sm is
assigned with a label k denoting the k-th subclass set
1 ≤ k ≤ K , 1 ≤ k ≤ K , where K is the total number of sub-
classes and ck is the index of the subclass with the label k,
and |ck| represents the number of samples with the same
label k.
Flowchart of analysis
POC allows us evaluate the similarity of disease samples
in frequency domain based on their GEPs. Figure 1
shows the flowchart of the proposed method for
predicting the type of a disease sample. This method is
essentially equivalent to a special case of 1NN classifica-
tion method with just one virtual sample per subclass in
training set. The procedure involves the following steps:
1) The entire sample set is randomly split into two
disjoint parts: a training set and a test set. We then
select a certain number of DEGs or differentially
expressed proteins (DEPs) using the Kruskal-Wallis rank
sum test (KWRST) method [37].
2) A virtual sample template for each subclass of
training set is constructed by averaging all samples in
the subclass. The j-th component of virtual sample tem-
plate for subclass ck is μk,j = (
∑
i∈ck xi,j)/|ck|, 1 ≤ j ≤ N ,
the mean expression of the k-th subclass in training set
for feature j. Thus the concept of virtual sample tem-
plate is the same as the centroid proposed in [38].
3) The POC function is calculated between each vir-
tual sample template and a test sample, both of which
are already transformed using the one-dimensional dis-
crete Fourier transform (1D DFT). The similarity
between each virtual sample template and a given test
sample is evaluated using the peak value of POC. The
formalized representation of a test sample matching
with all K templates is denoted by
rk = idft
(
imag
(
poc
(
dft
(
ftest
)
, dft (μk)
)))
, 1 ≤ k ≤ K (1)
where dft(.), poc(.), imag(.), and idft(.) denote discrete
Fourier transform (DFT), POC function, taking only
phase, and inverse discrete Fourier transform (IDFT),
respectively. Thus the peak vector (peak (1) , · · · , peak(K))
of the test sample ftest matching with all K templates can
be calculated by
peak (k) = max (rk) , 1 ≤ k ≤ K. (2)
4) The highest peak of POC can be utilized to deter-
mine the label of the test sample ftest, that is, the label
of the test sample is assigned by
C
(
ftest
)
= k∗ = arg maxkpeak(k). (3)
If we adopt a square matrix to represent a sample
instead of the vector form of the sample, we can analyze
Table 1 The summary of the seven complex disease datasets.
Datasets Platform #Samples #Features #Subclasses(K)
Leukemia1 Affy HGU95a 72 12,582 3
GSE29676 Invitrogen ProtoArray v5.0 119 9,480 3
Leukemia2 Affy HU6800 72 7,129 3
SRBCT cDNA 83 2,308 4
GSE5281 Affy HG-U133 161 54,675 2
Colon Affy HUM6000 62 2,000 2
GCM Affy HU6800 190 16,063 14
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a sample set using two-dimensional POC (2D POC) to
identify disease types. The flowchart of 2D POC analysis
method is very similar to the 1D POC shown in Figure 1.
The only difference is that 1D DFT and 1D IDFT in
Figure 1 are replaced with 2D DFT and 2D IDFT, respec-
tively. In fact, we can easily convert a sample vector
(assuming that the length of the sample vector is a square
number) into a square matrix easily.
Phase-only correlation
We adopt both 1D POC and 2D POC methods to analyze
disease samples. Here we only give the mathematical
description of 1D POC. The principle of 2D POC can be
found in literature [28]. Given two samples fa(n) ∈ S and
fb(n) ∈ S, here we assume that their index ranges are
n = −Q · · · Q, and T = 2Q + 1 for mathematical simplicity,
where Q is an integer. Let Fa (n) and Fb (n) denote the
one-dimensional discrete Fourier transform (1D DFT) of
two samples fa(n) and fb(n), respectively. They are given
by
Fa (n) =
∑Q
l=−Q fa(l)W
ln
T = AFa (n)e
jθFa (n) (4)
Fb (n) =
∑Q
l=−Q fb(l)W
ln
T = AFb (n)e
jθFb (n) (5)
where n = −Q · · · Q and WT = e−j2π/T. AFa and AFb are
amplitude components, and ejθFa (n) and ejθFb (n) are phase
components. The cross-phase spectrum R(n) is defined
as
R (n) =
Fa (n) Fb (n)∣∣Fa (n) Fb (n)
∣∣ = e
−jθ(n) (6)
where Fb(n) denotes the complex conjugate of Fb(n)
and θ (n) = θFa (n) − θFb(n) denotes the phase difference.
Only the phase information is utilized while the ampli-
tude is discarded because phase information is signifi-
cantly more important than amplitude information in
preserving the properties of intrinsic pattern [27]. Thus
the 1D inverse DFT (1D IDFT) of R(n) is denoted as
r (n) =
1
T
∑Q
l=−Q R(l)W
−ln
T (7)
where r(n) is the 1D POC function between fa(n) and
fb(n), and its value has a range from 0 to 1. The correlation
peak value of r(n) provides a measure of the similarity
between the two samples. Usually, the larger the peak value
is, the more similar the two samples are, and vice versa. The
peak value decreases when the noise in a test sample and
the constructed templates increase [28]. Thus high-level
noise in samples may degrade the accuracy of prediction.
In contrast to the template-based POC method, we
design a POC1DKNN method that utilizes 1D POC to
measure the similarity of two samples and apply 5-near-
est neighbor (5NN) to predict the label of test sample.
Experimental methods
Although there is no parameter in the proposed
method, the different number of pre-selected features
 
Figure 1 The flowchart of applying POC analysis to identify disease types. 1D DFT: one-Dimensional Discrete Fourier Transform; 1D IDFT:
one-Dimensional Inverse Discrete Fourier Transform; Template k denotes the k-th template constructed using training set.
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and the different divisions of training sets and test sets
can also affect the classification performance. To obtain
objective results, the Balance Division Method (BDM) is
used to divide each original dataset into balanced train-
ing sets and test sets [26]. For the BDM, Q samples
from each subclass of the original dataset are randomly
selected and used as a training set, while the remaining
samples are used as test set. For example, if we set Q to
5 for the SRBCT dataset, then 5 samples per subclass
are randomly selected, that is, 4 × 5 = 20 samples are
used as a training set and the rest 83 − 20 = 63 samples
are assigned to a test set. Considering that 2D POC
requires the square number of features selected, we
select 152, · · · , 302 features using KWRST to evaluate
the performance of POC method because the number of
genes or proteins related to complex diseases is
unknown and likely different from one disease to an-
other.
Results
Visualization of experimental results
The results of 1D POC and 2D POC can be visually repre-
sented. Taking the SRBCT dataset as an example, 1D
cross-correlation coefficients calculated by a test sample
(belonging to EWS subtype) matching with the four tem-
plates corresponding to the four subtypes of the SRBCT
dataset are shown in Figure 2 (a), (b), (c) and 2(d), respec-
tively. Their matching peak values are 0.7213, 0.2153,
0.2154, and 0.1889, respectively, suggesting the test sample
can be correctly assigned to EWS subtype based on these
values. Figure 3 shows 2D cross-correlation coefficients
calculated for a test sample (belonging to EWS subtype)
compared to the four templates of the SRBCT dataset.
Their matching peak values are 0.7118, 0.1971, 0.1487,
and 0.1471, respectively. Thus this test sample can be
easily assigned to EWS subtype.
The resulting separability of all test samples (belonging
to the same subclass) matching with each template can be
visualized using plots, from which we can visually deter-
mine which test sample is correctly or mistakenly classi-
fied. For example, Figure 4, obtained using POC based on
the training set selected randomly with 5 samples per sub-
class from the SRBCT dataset, shows the separability of
the four subtypes of the SRBCT dataset in four subplots,
respectively. In each subplot, the abscissa axis denotes the
sequence number of all test samples within the same sub-
class, and the ordinate axis denotes the similarity degree
(peak value) calculated by matching test samples with
each template. To make it clearer, in each subplot we con-
nect the points belonging to the same subclass to demon-
strate the separability of different subclasses. Figure 4
clearly shows that all test samples in the two subtypes (BL
and NB) are correctly classified, but the classification of
the EWS subtype is not perfect.
Comparison with other methods
Comparison with MACE method
Due to the fact that the OTSDF is a method with one
parameter and the performance of OTSDF and MACE
are almost equivalent, for fairer comparison we do not
compare POC with OTSDF in performance, while we
only compare the performance of POC with the one of
Figure 2 1D cross-correlation coefficient calculated by a test sample (belonging to EWS) matching with the four templates of the
SRBCT dataset, respectively. (a) EWS subtype. (b) BL. (c) NB. (d) RMS.
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Figure 3 2D cross-correlation coefficient calculated by a test sample (belonging to EWS subtype) matching with the four templates of
SRBCT. (a) EWS subtype. (b) BL. (c) NB. (d) RMS.
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Figure 4 The separability of all test samples in the SRBCT dataset. (a) The separability of all test samples belonging to EWS subtype. (b) BL.
(c) NB. (d) RMS.
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MACE. Like POC, MACE is also a nonparametric
method that has shown good performance on recogniz-
ing tumor subtypes [26]. However, the performance of
MACE is sensitive to the data scaling method used to
standardize the data. POC does not require data scaling
and thus it can avoid this problem. We fix the number of
the selected genes to 182 and assess the classification per-
formance varies with regard to different sample size of
training set. Figure 5 shows the comparison of perfor-
mance for POC and MACE on six disease datasets, where
each original dataset is divided into a balanced training set
and a test set by using the BDM method with Q varying
from 5 to |cmin|, where cmin = argminci (|ci|), 1 ≤ i ≤ K . If
|cmin| > 25, then the Q value takes from 5 to 25. The com-
parison clearly shows that POC outperforms MACE in
predictive accuracy on all six datasets (note that for the
GSE29676 dataset only when the number of training sam-
ples is larger than 12, and MACE is obviously superior to
POC in performance; for the SRBCT dataset only when
the number of training samples is lesser than 7, and
MACE is slightly superior to POC in performance).
Comparison with other model-based methods
Since the template-based POC method can be used to
build classifiers, we compare it with other state-of-the-
art model-based classification algorithms including
NBM, KNN, PNN, and SVM. For KNN, we set its k to
5 and adopt the correlation distance (one minus the
sample correlation between points) as the measure
between two samples, where the correlation distance is
computed by the following formula.
dst = 1 −
(xs − xs)
(
yt − yt
)′
√
(xs − xs) (xs − xs)′
√(
yt − yt
) (
yt − yt
)′ (8)
where xs =
1
n
∑
j xsj and yt =
1
n
∑
j ytj.
For PNN, there is a smoothing parameter σ to be tuned
within the range of [01]. To determine the optimal σ
value, 5-fold cross-validation (5-fold CV) is performed by
taking σ value from 0 to 1 by step 0.1 on each training
set divided randomly on original dataset using BDM. The
optimal σ is the one with the best performance of 5-fold
CV. For SVM, radial basis function (RBF) kernel is used
as the kernel function of SVM. There are two parameters,
C and γ, to be tuned. We use 5-fold CV on training set to
determine the optimal combination of the parameters C
and γ by screening all combinations of the following C
and γ: C = {21, 22, · · · , 216}, and γ = {2−5, 2−4, · · · , 216}.
Because SVM requires data scaling, each dataset is stan-
dardized into one with zero mean and unit variance.
Therefore, to obtain fairer comparison data scaling pre-
process is performed before classification.
Because the performance of a model is sensitive to data
division into training and test sets, we repeat the proce-
dure 200 times using randomly divided training and test
sets and report the mean value of the 200 predictive
accuracies for each method (Figure 6). Figure 6 shows the
performance of seven methods with regard to different
number of training samples per subclasses. Both POC1D
and POC2D perform well and are slightly superior to
POC1DKNN except on the GSE5281 dataset. Overall, our
methods achieve optimal or near-optimal performance.
We then fix the number of training samples per sub-
class to 8 but use different number of selected features
and study the performance of models for each dataset
(Figure 7). The results show that the performance of our
method is very robust with regard to the number of fea-
tures. KNN slightly outperforms our methods only on
the Leukemia2 and GSE5281 datasets, but it is obviously
inferior to our methods on the GSE29676 and SRBCT
datasets. We have also studied the effects of using other
feature filter methods such as t-test instead of KWRST,
and the experimental results indicate that different fea-
ture filters affect less the performance of the POC-based
method.
Comparison with feature extraction-based methods
Due to the high dimensionality of dataset, feature extrac-
tion is often used to reduce the dimensionality of dataset
before classification, and it plays a crucial role in simplify-
ing classification model and improving the classification
performance. Here we compare our method with five
dimensionality reduction methods, i.e., PCA, LDA, ICA,
LLDE, and LPP, which are extensively applied into the
classification of complex disease. Our previous study sug-
gests that the prediction accuracy depends less on classifi-
cation methods [39] when the number of features
extracted is small enough. Thus we also adopt the simplest
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classification method k-nearest neighbor (KNN) with cor-
relation distance to classify disease samples, and fixedly set
its k to 5.
To avoid over-fitting, before classification we extract
only 5 features adopting these feature extraction methods
except LDA whose number extracted is K − 1. Due to
these feature extraction methods require data normaliza-
tion, so each dataset has been sample-wise normalized to
zero mean and one variance after feature selection. We
call these methods as PCAKNN, LDAKNN, ICAKNN,
LLDEKNN, and LPPKNN, respectively. To further valid
the effectiveness of our method on multiclass dataset, we
select the GCM dataset with 14 different tumor types to
evaluate the performance of our method. Figure 8 shows
the performance of eight methods with regard to different
number of training samples per subclasses. The results
indicate that the performance of POC1D and POC2D are
almost the same and slightly superior to POC1DKNN.
Although LDAKNN outperforms POC on the GCM data-
set, on the Colon dataset POC outperforms LDAKNN.
Our method can achieve optimal or near-optimal perfor-
mance and has clear biomedical meaning, compared with
other five feature extraction-based methods. Furthermore,
for each dataset we also fix the number of training samples
per subclass to 8, and study the performance varying with
the number of selected features, as shown in Figure 9,
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Figure 7 The performance of eight methods varying with the number of features on the six datasets.
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indicating that the performance of these methods is robust
with regard to the number of genes and our method can
also achieve the best or near-optimal performance except
LDAKNN on the GCM dataset. To conclude, our novel
method is very effective and can obtain the best and near-
optimal performance.
Permutation assessment
To further assess the reliability of the proposed method,
we calculate the label permutation-based p-values [40] of
the six datasets. For each dataset we fix the number of
training samples in each subclass to 8 and the number of
initially selected features to182. First we perform r = 1000
randomizations of training sets and test sets, and then for
each randomization we randomly permute the labels of
the test set l = 50 times while keeping the labels of train-
ing set original. Therefore r × l = 1000 × 50 predictive
values are obtained, which are denoted as matrix
Accij, 1 ≤ i ≤ r, 1 ≤ j ≤ l . For each randomization, l = 50
predictive values are averaged, which is denoted as
Mean Acci, 1 ≤ i ≤ r . The final mean can be calculated by
p. p-Values can be calculated by
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Figure 8 The performance of eight methods varying with the number of training samples per subclass on the six datasets.
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Figure 9 The performance of eight methods varying with the number of features on the six datasets.
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p =
∣∣∣
{
S′ ∈ Ŝ : Acc(POC, S′) ≥ Acc(POC, S)
}∣∣∣ + 1
r × l + 1 ,
(9)
where Ŝ denotes a set of r × l randomized version S′ of
the original dataset S and Acc(POC, S′) denotes the pre-
dictive accuracy obtained using POC on dataset S′.
Acc(POC, S) denotes the mean of 200 predictive accu-
racy using POC on 200 randomizations of training set
and test set obtained on original dataset. Table 2 shows
the results of permutation tests with r = 1000 and l = 50
using the template-based POC1D and POC2D methods
on the six datasets. It is clear that the obtained classifi-
cation performance is reliable because their p-values are
very small. The mean value Bmean of predictive accuracy
with label permutation for each dataset is close to 1/K
except the Leukemia2, SRBCT and GCM datasets (for
the Leukemia2 and SRBCT datasets there is only one
sample in a subclass in test set, and for the GCM data-
set there are few or several samples in many subclasses
in test set), where K is the number of subclasses in data-
set, indicating that no bias occurred in the obtained
results [22].
Discussions
Data scaling or normalization is a very important data pre-
processing step for many machine learning algorithms
sensitive to the numeric ranges of attributes. There are
several widely used scaling methods such as Z-score that
transforms data into the one with zero-mean and one-
variance, and 0-1 scaling method that transforms data into
the range between 0 and 1, etc. Currently it is difficult to
predict what is the best data scaling method for a given
dataset [41], and no clear standard criterion can be used
to evaluate various scaling methods [42]. Besides, informa-
tion such as dynamic ranges might be lost during data
scaling. Therefore the proposed method is advantageous
over those demanding a scaling process because it does
not require data scaling.
In the present study, we construct the template of
each subtype using the means of the data points in the
training dataset. The results demonstrate that this
approach is reasonable and good performance is
achieved. Nevertheless, there are certainly other ways to
construct templates. For example, medians, instead of
means, are another possible approach that might be
more suitable for data that are not normally distributed.
For the present study, we test medians but do not find
significant difference from means (data not shown).
Thus only the results using means are reported.
Conclusions
A POC-based method is reported as a new technique for
identifying similar gene expression signatures for the dif-
ferentially expressed genes or proteins. By measuring the
similarity between a test sample and the virtual sample
templates constructed on training set for each subclass,
the label of the test sample can be easily determined.
Applying the POC-based classification method to six
complex disease datasets shows that this novel method is
feasible, efficient and robust. Compared with five state-
of-the-art classification algorithms and five feature
extraction-based methods, the proposed method can
achieve optimal or near-optimal classification accuracy.
Our methods can detect the similarity of overall pattern
while ignoring small mismatches between a giving test sam-
ple and templates because correlation filters are based on
integration operation. Compared with the MACE and
OTSDF methods, POC is not sensitive to data scaling meth-
ods. The experimental results show that the POC-based
method can achieve satisfactory results even without scaling
data. Moreover, there is no parameter to be tuned in POC,
so this method can easily avoid the over-fitting problem as
well as the effects of dimensionality curse. One possible
drawback of this novel method is that high-level noise in the
template can suppress the output peak. Our future work will
focus on exploring novel method to construct more repre-
sentative template to further improve predictive accuracy.
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